Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Arzerra gets breakthrough designation for first-line CLL

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and partner Genmab A/S (CSE:GEN) said FDA granted breakthrough therapy designation to

Read the full 167 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE